Tirzepatide is a synthetic 39-amino acid peptide that acts as an agonist at two receptors: GIP and GLP-1. In the SOMA Research catalogue it is listed under the designation GLP-2 TZ. This guide covers the molecule’s structure, why its receptor balance is unusual, how it is characterised analytically, and how to handle it in the laboratory. It is written for researchers evaluating the compound for in vitro and preclinical work.
SOMA Research supplies tirzepatide for laboratory research use only. It is not a drug, supplement, food or cosmetic, is not approved by the FDA for any use, and is not intended for human or veterinary consumption.
What tirzepatide is
Tirzepatide is a lipidated peptide built on the native GIP sequence rather than on GLP-1. Its published identifiers are:
- CAS number: 2023788-19-2
- Molecular weight: 4,813.45 g/mol
- Length: 39 amino acids
- Lipidation: a C20 diacid fatty-acid chain
- Catalogue designation: GLP-2 TZ
- PubChem: CID 166567236
Two structural features that define it
Aib substitutions. Tirzepatide carries α-aminoisobutyric acid (Aib) in place of natural residues at positions 2 and 13. Aib is a non-proteinogenic amino acid with two methyl groups on the α-carbon. Position 2 is the site dipeptidyl peptidase-4 (DPP-4) cleaves in native incretins, and substituting Aib there blocks that cleavage. This is why tirzepatide survives in plasma where native GIP has a half-life measured in minutes.
C20 diacid acylation. A twenty-carbon fatty diacid is attached through a linker to a lysine side chain. The chain binds reversibly to serum albumin, which slows renal filtration and extends circulating half-life. Acylation is the single biggest determinant of how a peptide behaves in a pharmacokinetic model, and it is also what makes the molecule more difficult to synthesise and purify than an unmodified sequence of the same length.
Why the receptor balance matters
Tirzepatide is usually described as an “imbalanced” or GIP-biased dual agonist. Published binding work reports affinity at the GIP receptor comparable to native GIP, but affinity at the GLP-1 receptor several-fold lower than native GLP-1. It is not an equipotent dual agonist, and that asymmetry is a deliberate design feature rather than an artefact.
For in vitro work this has a practical consequence: a single concentration will not engage both receptors to the same fractional occupancy. Experiments intended to probe the GLP-1 arm need concentrations high enough to reach it, by which point the GIP arm is near-saturated. Researchers separating the two contributions generally use receptor-selective antagonists or cell lines expressing one receptor rather than relying on concentration alone.
Where it sits among related peptides
| Compound | Receptor targets | Class | Backbone |
|---|---|---|---|
| Semaglutide | GLP-1 | Mono-agonist | GLP-1 |
| Tirzepatide (GLP-2 TZ) | GIP + GLP-1 | Dual agonist | GIP |
| Retatrutide (GLP-3 RT) | GIP + GLP-1 + glucagon | Triple agonist | GIP |
Tirzepatide and retatrutide are both 39 residues, both GIP-backbone, both C20-acylated. The difference is the glucagon-receptor arm that retatrutide adds. Running the two side by side is the cleanest available way to isolate what glucagon-receptor engagement contributes, because so much else is held constant between them.
Research context
Tirzepatide was developed by Eli Lilly under the code LY3298176 and has been the subject of an extensive published clinical programme. That programme concerns a pharmaceutical product manufactured to pharmaceutical standards; it is referenced here only as the published literature on the molecule. Research-grade tirzepatide supplied for laboratory use is not that product and must not be used in or on humans or animals.
The preclinical literature most relevant to laboratory work covers receptor binding and selectivity panels, cAMP accumulation and β-arrestin recruitment assays at GIPR and GLP-1R, receptor trafficking and internalisation behaviour, and metabolic phenotyping in rodent models. The internalisation work is worth noting: biased signalling at GLP-1R, where cAMP response is preserved while β-arrestin recruitment and receptor internalisation are reduced, is one of the mechanistic explanations offered for the compound’s profile and is a frequent subject of in vitro replication.
Purity and identity: what to require
A 39-residue peptide containing two non-natural residues and a lipid conjugation has more ways to go wrong in synthesis than a short sequence does. Two analytical results matter, and neither substitutes for the other.
HPLC for purity
High-Performance Liquid Chromatography reports the target peptide as a percentage of total peak area. The realistic impurities in a molecule like this are deletion sequences, incompletely deprotected material, and — specific to acylated peptides — unacylated or doubly-acylated species. The unacylated form differs from the target by the mass of the fatty-acid chain and is the impurity most worth asking about, because it is a different pharmacological entity, not merely a contaminant.
Mass spectrometry for identity
Mass spectrometry confirms the observed mass matches the theoretical 4,813.45 g/mol for the intended sequence and modification. HPLC tells you a sample is homogeneous; MS tells you it is the right molecule. A certificate with one and not the other answers half the question.
Current lots are documented on the Certificates of Analysis page, with both assays reported per batch. How to Read a Certificate of Analysis explains the fields and the common ways a certificate can look convincing without saying much.
Handling and stability
- Lyophilised powder: stable at −20°C for 24+ months, kept dry and protected from light.
- Reconstituted solution: approximately 30 days at 2–8°C.
- Freeze-thaw: aliquot after reconstitution rather than refreezing a stock vial.
- Agitation: swirl or roll to dissolve. Vortexing generates foam, and the air-water interface in foam promotes aggregation of acylated peptides.
- Temperature on opening: let the vial equilibrate to room temperature before breaking the seal. Lyophilised peptide is hygroscopic and a cold vial condenses atmospheric moisture onto the powder.
Frequently asked questions
What is tirzepatide?
Tirzepatide is a synthetic 39-amino acid peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It is built on the GIP sequence, carries Aib substitutions at positions 2 and 13 and a C20 diacid fatty-acid chain, and has CAS number 2023788-19-2 and a molecular weight of 4,813.45 g/mol. SOMA Research lists it as GLP-2 TZ and supplies it for laboratory research use only.
Why does SOMA list tirzepatide as GLP-2 TZ?
GLP-2 TZ is an internal catalogue designation used on product labelling and in the shop. It refers to the same compound, tirzepatide, CAS 2023788-19-2. Each product page states the CAS number and molecular weight so the identity is unambiguous.
Is tirzepatide a balanced dual agonist?
No. Published binding data report affinity at the GIP receptor comparable to native GIP but affinity at the GLP-1 receptor several-fold lower than native GLP-1. It is commonly described as GIP-biased or imbalanced, and that asymmetry should be accounted for when choosing concentrations for in vitro work.
What is the difference between tirzepatide and retatrutide?
Both are 39-residue, C20-acylated peptides on a GIP backbone. Tirzepatide engages the GIP and GLP-1 receptors. Retatrutide engages those two plus the glucagon receptor, making it a triple agonist.
Why do Aib substitutions matter?
α-aminoisobutyric acid at position 2 blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native incretin peptides. Together with fatty-acid acylation, this is what gives the molecule a long circulating half-life compared with native GIP.
How should research-grade tirzepatide be stored?
Store the lyophilised powder at −20°C protected from light, where it is stable for 24 months or more. Once reconstituted, keep it at 2–8°C and use within about 30 days, aliquoting rather than refreezing.
Related guides
- HPLC vs mass spectrometry: why a CoA needs both
- Peptide storage and stability
- How to reconstitute a research peptide
- Retatrutide vs tirzepatide compared
SOMA Research products are intended for laboratory and research use only. They are not drugs, foods, cosmetics, or supplements, are not intended to diagnose, treat, cure, or prevent any disease or condition, and are not for human or animal consumption. Nothing on this page is medical advice.
